Corticotropin-releasing factor antagonists in affective disorders

Bibliography

• VALE W, SPEISS J, RIVIER C, RIVIER J: Characterization ofa 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 213:1394–1397.
   PubMed Web of Science ®Google Scholar
• OWENS MJ, NEMEROFF CB: Physiology and pharma-cology of corticotropin-releasing factor. Pharmacol Rev (1991) 43:425–473.
   PubMed Web of Science ®Google Scholar
• ••Detailed critical review of early CRF literature.
   Google Scholar
• SWANSON LW, SAWCHENKO PE, RIVIER J, VALE WW:Organization of ovine corticotropin-releasing facotr immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology (1983) 36:165–186.
   PubMed Web of Science ®Google Scholar
• HEIT S, OWENS MJ, PLOTSKY PM, NEMEROFF CB:Corticotropin-releasing factor, stress, and depression. The Neuroscientist (1997) 3:186–194.
   Web of Science ®Google Scholar
• •Short overview of rationale for development of CRF antagonists.
   Google Scholar
• CHALMERS DT, LOVENBERG TW, GRIGORIADIS DE, BEHAN DP, DESOUZA EB: Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. ScL (1996) 17:166–172.
   PubMed Web of Science ®Google Scholar
• ••Best short review of receptor pharmacology and molecularbiology.
   Google Scholar
• VAUGHAN J, DONALDSON C, BITTENCOURT J et al.: Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 378:287–292.
   PubMed Web of Science ®Google Scholar
• LOVENBERG TW, CHALMERS DT, LIU C, DE SOUZA EB:CRF2 and CRF2 receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology (1995) 136:4139–4142.
   PubMed Web of Science ®Google Scholar
• CHALMERS DT, LOVENBERG TW, DE SOUZA EB:Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcor-tical nuclei in rat brain: comparison with Clifi receptor mRNA expression. J. Neurosci. (1995) 15:6340–6350.
   PubMed Web of Science ®Google Scholar
• RICHARD D, RIVEST R, NAIMI N,TIMOFEEVA E, RIVEST S: Expression of corticotropin-releasing factor and its receptors in the brain of lean and obese Zucker rats. Endocrinology (1996) 137:4786–4795.
   PubMed Web of Science ®Google Scholar
• SANCHEZ MM, YOUNG LJ, PLOTSKY PM, INSEL TR: Autoradiographic and in situ hybridization localiza-tion of Clifi and CRF2 receptors in nonhuman primate brain. J. Comp. Neurol. (1999) 408:365–377.
   PubMed Web of Science ®Google Scholar
• •Detailed anatomical distribution of CRF receptor binding and mRNA expression in nonhuman primate brain.
   Google Scholar
• ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The role of corticotropin-releasing factor in depres-sion and anxiety disorders. J. Endocrinol. (1999) 160:1–12.
   PubMed Web of Science ®Google Scholar
• •Most recent review of neurobiology of CRF and potential clinical implications.
   Google Scholar
• NEMEROFF CB: The neurobiology of depression. Sci. Am. (1998) 278 (6):42–49.
   PubMed Web of Science ®Google Scholar
• PLOTSKY PM, OWENS MJ, NEMEROFF CB: Psychoneuro-endocrinology of depression: hypothalamic-pituitary-adrenal axis. PsychiaL Clin. North Am. (1998) 21:293–307.
   PubMed Web of Science ®Google Scholar
• ••Preclinical and clinical rationale for CRF antagonistdevelopment
   Google Scholar
• LIAW CW, GRIGORIADIS DE, LOVENBERG TE et al.: Localization of ligand binding domains of the human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol. Endocrinol. (1997) 11:980–985.
   PubMed Web of Science ®Google Scholar
• LIAW CW, GRIGORIADIS DE, LORANG MT et al.: Localiza-tion of agonist and antagonist binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol. (1997) 11:2048–2053.
   PubMed Web of Science ®Google Scholar
• CHRISTOS TE, ARVANTIS A: Corticotrophin-releasing factor receptor antagonists. Exp. Opin. Ther. Pat. (1998) 8:143–152.
   Web of Science ®Google Scholar
• ••Detailed description of chemical structures of putative CRFreceptor antagonists.
   Google Scholar
• McCARTHY JR, HEINRICHS SC, GRIGORIADIS DE: Recent progress in corticotropin-releasing factor receptor agents. Ann. Rep. Med. Chem. (1999) 34: 11–20.
   Web of Science ®Google Scholar
• ••Review of rationale and description of chemical structures ofputative CRF receptor and CRF-BP antagonists.
   Google Scholar
• McCARTHY JR, HEINRICHS SC, GRIGORIADIS DE: Recentadvances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr. Pharma. Design (1999) 5:289–315.
   PubMed Web of Science ®Google Scholar
• SCHULZ DW, MANSBACH RS, SPROUSE J et al.: CP-154,526: a potent and selective nonpeptide antago-nist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. USA (1996) 93:10477–10482.
   PubMed Web of Science ®Google Scholar
• ••First paper describing pharmacology of a small moleculeCRF1 antagonist.
   Google Scholar
• LUNDKVIST J, CHAT Z, TEHERANIAN R et al.: A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits amdolytic-like activity. Eur. j Pharmacol. (1996) 309(2):195–200.
   PubMed Web of Science ®Google Scholar
• MANSBACH RS, BROOKS EN, CHEN YL: Antidepressant-like effects of CP-154,526, a selective Clifi receptor antagonist. Eur. J. Pharmacol (1997) 323:21–26.
   PubMed Web of Science ®Google Scholar
• SHAHAM Y, ERB S, LEUNG S, BUCZEK Y, STEWART J:CP-15,526, a selective, non-peptide antagonist of the corticotropin-releasing factori receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (1998) 137:184–190.
   PubMed Web of Science ®Google Scholar
• CHEN YL, MANSBACH RS, WINTER SM et al.: Synthesis andoral efficacy of a 4- (butylethyl-amino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor receptori antagonist. J. Med. Chem. (1997) 40:1749–1754.
   PubMed Web of Science ®Google Scholar
• WEBSTER EL, LEWIS DB, TORPY DJ et al.: In vivo and invitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CM receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology (1996) 137:5747–5750.
   PubMed Web of Science ®Google Scholar
• BORNSTEIN SR, WEBSTER EL, TORPY DJ et al.: Chroniceffects of a nonpeptide corticotropin-releasing hormone Type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regula-tion. Endocrinology (1998) 139:1546–1555.
   PubMed Web of Science ®Google Scholar
• WONG M-L, WEBSTER EL, SPOKES H et al.: Chronic administration of the non-peptide CRH Type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci. (1999) 65:PL53–58.
   PubMed Web of Science ®Google Scholar
• DEAK T, NGUYEN KT, EHRLICH AL et al.: The impact ofthe nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioural and endocrine responses to stress. Endocrinology (1999) 140:79–86.
   PubMed Web of Science ®Google Scholar
• GILLIGAN PJ, HARTIG PR, ROBERTSON DW et al.:Corticotropin-releasing hormone (CRH) receptors and the discovery of selective non-peptide CRHi antagonists. Ann. Rep. Med. Chem.. (1997) 32: 41–50.
   Web of Science ®Google Scholar
• ROMINGER DH, ROMINGER CM, FITZGERALD LW et al: Characterization of [12511sauvagine binding to CR112 receptors: membrane homogenate and autoradio-graphic studies. J. Pharmacol Exp. Ther. (1998) 286:459–468.
   PubMed Web of Science ®Google Scholar
• •Use of CRF1 antagonists and subtractive autoradiography to quantify CRF2 receptors.
   Google Scholar
• ARVANITIS AG, GILLIGAN PJ, CHORVAT RJ et al: Non-peptide corticotropin-releasing hormone antago-nists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. J. Med. Chem. (1999) 42:805–818.
   PubMed Web of Science ®Google Scholar
• CHORVAT RJ, BAKTHAVATCHALAM R, BECK J et al.: Synthesis corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazolo-, and pyrrolopyrimidines and -pyridines. J. Med. Chem. (1999) 42:833–848.
   PubMed Web of Science ®Google Scholar
• HODGE CN, ALDRICH PE, WASSERMAN ZR et al.: Corticotropin-releasing hormone antagonists: framework design and synthesis guided by ligand conformation studies. J. Med. Chem. (1999) 42:819–832.
   PubMed Web of Science ®Google Scholar
• KALIN NH, SHELTON SE, ZACZEK R: The evaluation of CRF receptor antagonists in animal models. Proc. Am. Coll. Neuropsychopharmacol. Kona HI, USA (1997):19.
   Google Scholar
• HINDMAN C, DENT G, MCELROY JF, GILLIGAN P, HE L, SMITH MA: Effects of a non-peptide CRH antagonist on the HPA axis. Neuroendocrine Workshop on Stress sponsored by the American Neuroendocrine Society. New Orleans, USA (1998):42.
   Google Scholar
• MACIAG C, DENT G, HE L, GILLIGAN P, LEVINE S,SMITH MA: Non-peptide corticotropin releasing factor antagonists mitigate behavioral sequelae of maternal separation. Neuroendocrine Workshop on Stress sponsored by the American Neuroendocrine Society. New Orleans, USA (1998):43.
   Google Scholar
• ZACZEK R, FITZGERALD LW, MCELROY J et al: Novel small molecule Clifi receptor antagonists: identifica-tion and pharmacological characterization. Neuroen-docrine Workshop on Stress sponsored by the American Neuroendocrine Society. New Orleans, USA (1998):38.
   Google Scholar
• CHEN C, DAGNINO R, DE SOUZA EB et al: Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factori receptor antagonists. J. Med. Chem. (1996) 39:4358–4360.
   PubMed Web of Science ®Google Scholar
• WHITTEN JP, XIE YF, ERICKSON PE et al.: Rapid microscale synthesis, a new method for lead optimiza-tion using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factori receptor antagonists. J. Med. Chem. (1996) 39:4354–4357.
   PubMed Web of Science ®Google Scholar
• BARAM TZ, CHALMERS DT, CHEN C et al. The receptor mediates the excitatory actions of cortico-tropin releasing factor (CRF) in the developing rat brain in vivo: evidence using a selective non-peptide receptor antagonist. Society for Neuroscience Abstracts. New Orleans, USA (1997):689.9.
   Google Scholar
• LORANG MT, CHEN C, MCCARTHY JR, DE SOUZA EB, GRIGORIADIS DE: In vitro and ex vivo receptor occupancy studies of a selective non-peptide CRF1 receptor antagonist: NBI 27914. Society for Neuroscience Abstracts. New Orleans, USA (1997):689.10.
   Google Scholar
• Drug Report. INVESTIGATIONAL DRUGS DATABASE (1999) Current Drugs Ltd.
   Google Scholar
• ARAI K, OHATA H, SHIBASAKI T: Non-peptidic corticotropin-releasing hormone receptor Type 1 antagonist reverses restraint stress-induced shortening of sodium pentobarbital-induced sleeping time of rats: evidence that an increase in arousal induced by stress is mediated through CRH receptor Type I. Neurosci. Lett. (1998) 255:103–106.
   PubMed Web of Science ®Google Scholar
• OKUYAMA S, CHAKI S, KAWASHIMA N et al.: Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. (1999) 289:926–935.
   PubMed Web of Science ®Google Scholar
• CHAKI S, OKUYAMA S, NAKAZATO A et al: In vitro pharmacological profile of non-peptide Clifi receptor antagonists, CRA1000 and CRA1001. Eur. J. Pharmacol (1999) 371:205–211.
   PubMed Web of Science ®Google Scholar
• GRIGORIADIS DE, LORANG MT, DUGGAN N et al.: Therapeutic potential of specific CRF1 receptor antagonists. Proceedings of the American College of Neuropsychopharmacology. Kona HI, USA (1997):19.
   Google Scholar
• GRIGORIADIS DE, DE SOUZA EB: Small molecule CRF1 receptor antagonists: characterization and clinical application. Neuroendocrine Workshop on Stress sponsored by the American Neuroendocrine Society. New Orleans, USA (1998):36.
   Google Scholar
• MARTARELLO L, KILTS CD, ELY T, OWENS MJ, NEMEROFF CB, GOODMAN MM: Design, synthesis and evaluation of amino-anilino-pyrimidines as potential SPECT ligands for the Clifi receptor. International Society of Psychoneuroendocrinology Abstracts. Orlando, USA (1999):53.
   Google Scholar
• MARTARELLO L, KILTS CD, ELY T, OWENS MJ, NEMEROFF CB, GOODMAN MM: Design, synthesis and characterization of fluorinated- and iodinated-pyrrolo[2,3-d]pyrimidines as candidates for CRF1 receptor PET/SPECT ligands. J. Labelled Compounds Radiopharmaceut. (1999) 42 (S1):S312-S314. Michael J Owenst & Charles B Nemeroff tAuthor for correspondence Laboratory of Neuropsychopharmacology, Department of Psychiatry & Behavioural Sciences, Emory University School of Medicine, 1639 Pierce Drive, Suite 4000, Atlanta, Georgia, USA 30322 Tel.: +1 404 727 4059; Fax: +1 404 727 3233; Email: [email protected]
   Google Scholar